CytoMed Therapeutics Ltd., a clinical stage biopharmaceutical company based in Singapore, has announced the completion of dose level 1 in its ANGELICA Trial, a Phase I dose-escalation clinical trial. The trial evaluates the safety and tolerability of CTM-N2D, an allogeneic NKG2DL-targeting chimeric antigen receptor-grafted $(CAR)$ gamma delta T cell therapy, in patients with advanced solid tumors or haematological malignancies. The trial will now proceed to dose level 2, scheduled to begin in the third quarter of 2025. CTM-N2D utilizes gamma delta T cells from healthy donors, modified to target cancer cells, and can be administered without donor-patient compatibility matching. Further results from the trial have not yet been presented.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.